Alkermes
Update in progressALKS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Alkermes plc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that address unmet medical needs in the United States, Ireland, and internationally. Its portfolio includes proprietary treatments for opioid and alcohol dependence, and schizophrenia, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ, plus a pipeline for neurological disorders. It also provides technology platforms and collaborates with Janssen. Founded 1987, based in Dublin.
Company score
- Sentiment
- 0.50
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.28
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.30
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!